{"id":"NCT04353817","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","officialTitle":"A Phase 3b, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 6 Through 11 Years of Age Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-19","primaryCompletion":"2021-05-17","completion":"2021-05-17","firstPosted":"2020-04-20","resultsPosted":"2022-07-26","lastUpdate":"2022-07-26"},"enrollment":121,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]},{"type":"OTHER","name":"Placebo (matched to ELX/TEZ/IVA)","otherNames":[]},{"type":"OTHER","name":"Placebo (matched to IVA)","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).","primaryOutcome":{"measure":"Absolute Change in Lung Clearance Index 2.5 (LCI2.5)","timeFrame":"From Baseline Through Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.02,"sd":0.16},{"arm":"ELX/TEZ/IVA","deltaMin":-2.29,"sd":0.16}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":34,"countries":["Australia","Canada","Denmark","France","Germany","Israel","Netherlands","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":61},"commonTop":["Cough","Headache","Abdominal pain","Nasopharyngitis","Infective pulmonary exacerbation of cystic fibrosis"]}}